Login to Your Account



AD relief 'pitcher' bright: Regeneron, Sanofi score pair of phase III home runs for skin win

By Randy Osborne
Staff Writer

Friday, April 1, 2016

"We have cracked the code of atopic dermatitis [AD] disease pathology," Bola Akinlade, director of clinical sciences at Regeneron Pharmaceuticals Inc., told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription